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Abstract
Background: Human butyrylcholinesterase (huBChE) has been shown to be an effective antidote
against multiple LD50 of organophosphorus compounds. A prerequisite for such use of huBChE is
a prolonged circulatory half-life. This study was undertaken to produce recombinant huBChE fused
to human serum albumin (hSA) and characterize the fusion protein.
Results: Secretion level of the fusion protein produced in vitro in BHK cells was ~30 mg/liter.
Transgenic mice and goats generated with the fusion constructs expressed in their milk a bioactive
protein at concentrations of 0.04–1.1 g/liter. BChE activity gel staining and a size exclusion
chromatography (SEC)-HPLC revealed that the fusion protein consisted of predominant dimers
and some monomers. The protein was confirmed to have expected molecular mass of ~150 kDa
by Western blot. The purified fusion protein produced in vitro was injected intravenously into
juvenile pigs for pharmacokinetic study. Analysis of a series of blood samples using the Ellman assay
revealed a substantial enhancement of the plasma half-life of the fusion protein (~32 h) when
compared with a transgenically produced huBChE preparation containing >70% tetramer (~3 h). In
vitro nerve agent binding and inhibition experiments indicated that the fusion protein in the milk of
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transgenic mice had similar inhibition characteristics compared to human plasma BChE against the
nerve agents tested.
Conclusion: Both the pharmacokinetic study and the in vitro nerve agent binding and inhibition
assay suggested that a fusion protein retaining both properties of huBChE and hSA is produced in
vitro and in vivo. The production of the fusion protein in the milk of transgenic goats provided
further evidence that sufficient quantities of BChE/hSA can be produced to serve as a cost-effective
and reliable source of BChE for prophylaxis and post-exposure treatment.
Background
Poisoning with organophosphorus (OP) compounds is a
severe problem facing military personnel who may
encounter lethal doses of these compounds in chemical
warfare situations. Further, OP and other anticholineste-
rase agents are extensively used as pesticides and pose a
substantial occupational and environmental risk. Human
serum butyrylcholinesterase (huBChE, EC 3.1.1.8) is a
globular, tetrameric molecule with a molecular mass of
~340 kDa [1]. Administration of exogenous huBChE has
been shown to be an effective and safe alternative treat-
ment for the prevention of OP nerve agent toxicity [2-7],
although the physiological function of huBChE is largely
elusive. In addition, it can hydrolyze many ester-contain-
ing drugs such as cocaine and succinylcholine [8]. Of the
cholinesterases evaluated for nerve agent scavenging
potential so far, huBChE purified from plasma has a rela-
tively long half-life [9], a broad spectrum of activity
against a variety of nerve agents including sarin, soman,
tabun and VX, and limited, if any, physiological side
effects [4]. However, huBChE may not be a viable option
because it is only expressed at ~5 mg/liter in human
plasma [10] and production of large quantities needed for
civilian and military stockpiles is impractical. Recom-
binant huBChE has been expressed in bacteria [11] and in
mammalian cell lines [12,13]. However, these recom-
binant production strategies have not yet produced suffi-
cient quantities of functional BChE with a residence time
similar to native huBChE to allow the economically rea-
sonable development of recombinant enzyme as a pro-
phylactic indication against OP poisoning. Recently it has
been shown that large quantities of recombinant huBChE
can be produced in the milk of transgenic goats for proph-
ylaxis of humans at risk for exposure to OP nerve agents
[14,15]. One way to achieve plasma stability and longer
half-life of recombinant BChE while maintaining its bio-
logical activity is to provide a recombinantly produced
BChE fused to human serum albumin (hSA).
It is well known that hSA, the most abundant protein in
plasma, is a good carrier protein with a substantial circu-
latory half-life (up to 19 days in the human blood) and is
widely distributed in vivo [16]. A number of proteins have
been fused to albumin to improve their circulating half-
lives and stability characteristics [17-19]. It has been
reported that some therapeutic proteins genetically fused
with hSA in general have longer circulating half-lives and
improved pharmacokinetic and pharmacodynamic pro-
files compared to the non-fused proteins. Further, hSA has
been shown to covalently bind OP agents in vitro [20,21]
and in vivo, and therefore OP bound to hSA may serve as
a biomarker of OP exposure in humans [22]. We hypoth-
esized that it might be possible to delay the clearance of a
rapidly cleared recombinant BChE via fusion to this
slowly cleared plasma protein. This fusion protein may
exhibit high plasma stability in the body and is expected
to be either weakly or non-immunogenic for the organism
in which it is used [23]. In addition, an affinity column,
for example, an Affi-Gel Blue Gel column, can be used as
an additional purification procedure for the hSA fused
protein. Therefore, a series of DNA expression constructs
harboring the sequence encoding the mature hSA fused in
frame to the 3' end of the huBChE cDNA sequence with a
DNA sequence encoding a (Gly)6-Ser amino acid linker
were made. The fusion protein was produced first in vitro
in BHK cells and used in a pharmacokinetic study as a
proof-of-concept experiment, followed by fast generation
of transgenic mice. Milk samples containing the fusion
protein from a transgenic mouse were tested against a
variety of nerve agents. Further, transgenic goats were gen-
erated for large-scale production of the fusion protein.
Methods
Construction of in vitro DNA expression vector CMV/
BChE/hSA
Standard recombinant DNA methods employed herein
have been described in detail [24]. All DNA cloning
manipulations were performed using Escherichia coli
Stbl2™ competent cells (Invitrogen, Burlington, ON, Can-
ada). Restriction and modifying enzymes were purchased
from New England BioLabs (Ipswich, MA). All chemicals
used were reagent grade and purchased from Sigma-
Aldrich (Oakville, ON, Canada), unless otherwise speci-
fied. Construct integrity was verified using DNA sequenc-
ing service provided by Mobix Lab (McMaster University,
ON, Canada). Primers for sequencing and PCR were syn-
thesized by Sigma-Genosys (Oakville, ON, Canada). PCR
was performed using Ready-To-Go™ PCR beads (GE
Healthcare Life Sciences, Baie d'Urfe, QC, Canada) or anBMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
Page 3 of 11
(page number not for citation purposes)
Expand High Fidelity PCR kit (Roche Diagnostics, Laval,
QC, Canada).
The huBChE cDNA was amplified by PCR from cDNA
clone ATCC #65726 [25] (ATCC, Manassas, VA) with a
sense primer Acb787 (5' AGA GAG GGG GCC CAA GAA
GAT GAC ATC ATA ATT G 3') containing an ApaI site
(underlined), partial Ig kappa signal sequence and an
antisense primer Acb786 (5' CTG CGA GTT TAA ACT ATT
AAT TAG AGA CCC ACA C 3') including a PmeI site
(underlined) and partial 3' sequence of the huBChE
cDNA. The PCR product was digested with ApaI and
PmeI, purified using GFX matrix (GE Healthcare Life Sci-
ences) and ligated into ApaI-PmeI digested CMV688M4
(kindly provided by Dr. J. F. Zhou, then Nexia Biotechnol-
ogies, Inc.) to generate CMV/BChE. PCR was performed
using the CMV/BChE as a template with a sense primer
Acb710 (5' GTG TAA CTC TCT TTG GAG AAA G 3') con-
taining a portion of 5' BChE sequence and an antisense
primer Acb853 (5' TAT AAG TTT AAA CAT ATA ATT GGA
TCC TCC ACC TCC GCC TCC GAG ACC CAC ACA ACT
TTC TTT CTT G 3') containing a PmeI site (underlined), a
BamHI site (italic), a (Gly)6-Ser linker (bolded) followed
by a portion of 3' BChE sequence. The PCR product was
digested with XbaI, a restriction enzyme site located 185
bp downstream of the primer binding site of Acb710, and
PmeI, and ligated to XbaI-PmeI digested CMV/BChE to
generate an intermediate vector, CMV/BChEmd.
PCR was performed using Marathon-Ready™ human liver
cDNA pool (Clontech, Mountain View, CA) as a template
with a sense primer Acb854 (5' ATA TAA GGA TCC GAT
GCA CAC AAG AGT GAG GTT GCT CAT C 3') containing
a BamHI site (underlined) and partial sequence from the
hSA cDNA 5' end (GenBank accession #V00495, without
the signal sequence), and an antisense primer Acb855 (5'
ATT TAA GTT TAA ACT CAT TAT AAG CCT AAG GCA GCT
TGA CTT GC 3') including a PmeI site (underlined) and
partial sequence from the hSA cDNA 3' end. This PCR
product was digested with BamHI and PmeI, and inserted
into BamHI-PmeI digested CMV/BChEmd to generate the
final construct, CMV/BChE/hSA.
Construction of in vivo DNA expression vectors
A DNA expression vector bCN/BChE [14] was digested
with XhoI to remove the BChE insert. The BChE-less vec-
tor was blunt-ended by filling in with Klenow polymerase
in the presence of dNTPs, and calf intestine alkaline phos-
phatase treated. The in vitro DNA expression vector CMV/
BChE/hSA (see described above) was partially digested
with NcoI to remove the BChE/hSA encoding sequences.
The BChE/hSA fragment was blunt-ended by filling in
with Klenow polymerase in the presence of dNTPs, and
PmeI digested. The two blunt-ended fragments were
ligated to generate bCN/BChE/hSA for pronuclear micro-
injection to produce transgenic mice. PCR cloning was
performed to insert a neomycin fragment between the
insulators and the β-casein promoter [14] in bCN/BChE/
hSA to generate Neo-bCN/BChE/hSA for nuclear transfer
in transgenic goats. For all the in vivo DNA expression vec-
tors, the signal sequence is either from goat β-casein or
BChE itself. Linear DNA (NotI digestion), free of bacterial
sequences, was prepared [14]. DNA was quantified using
a fluorometer and stored at 4°C.
Transfection and selection of stable cell lines
BHK cells were transfected with Lipofectamine PLUS Rea-
gent (Invitrogen) as per the manufacturer's recommenda-
tions using 4 µg of the CMV/BChE/hSA DNA. Briefly, the
DNA was diluted to a final volume of 750 µl with DMEM
(Invitrogen) and 20 µl of PLUS Reagent was added to the
mixture. The Lipofectamine was diluted to a final volume
of 750 µl with DMEM. After incubation at room tempera-
ture for 15 min, the Lipofectamine and DNA mixtures
were combined and complexes were allowed to form for
15 min at room temperature. The lipid-DNA complex
mixture was applied to BHK cells (ATCC), and the cells
were allowed to incubate for 3 h at 37°C under 5% CO2.
The cells were then cultured for another 24 h in fresh
medium containing 20% fetal bovine serum (Invitrogen).
Subsequently, stably transfected cells were selected in
DMEM containing 10% fetal bovine serum and 300 µg/
ml hygromycin B (Invitrogen). Colonies surviving selec-
tion were picked 7 to 14 days following transfection and
expanded further.
The level of BChE activity in cell culture media from CMV/
BChE/hSA transfected BHK cells was evaluated using a
commercially available kit (Sigma-Aldrich). From over
100 clones tested, the one demonstrating the highest
BChE activity (Clone 35) was further evaluated in roller
bottles containing serum-free DMEM. A master cell bank
was generated and used to initiate a hollow fiber bioreac-
tor (CP2500 model, Biovest International, Worcester,
MA) production run. Hollow fiber production of stable
transfectants was established to produce the fusion pro-
tein.
Production of founder and subsequent generation of 
transgenic animals
The production and maintenance of transgenic mice were
conducted at the McIntyre Transgenic Core Facility of
McGill University (Montreal, QC, Canada). Animal stud-
ies were carried out in accordance with Guidelines on the
care and use of experimental animals from the Canadian
Council of Animal Care (CCAC). Transgenic mice were
generated essentially as described in [26] in a Friend virus
B-type (FVB) background strain (Charles River Laborato-
ries, Wilmington, MA). The bCN/BChE/hSA transgene
was microinjected into the pronuclei of fertilized eggs,BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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and 31 pups were born. At 2–3 weeks of age tail biopsies
were taken, under anesthesia, and DNA was prepared
according to standard procedures [24]. Transgenic
founder mice were bred with wild-type mice of the same
strain for the production of F1 and F2 generations.
The production and maintenance of transgenic goats were
conducted at Caprine Production Farm (CPF) of then
Nexia Biotechnologies Inc. Animal studies were carried
out in accordance with Guidelines on the care and use of
experimental animals from CCAC. The production of the
founders and subsequent generation of transgenic goats
was performed by nuclear transfer as described in Keefer
et al. [27] using the DNA expression vector, Neo-bCN/
BChE/hSA.
PCR, Southern blot and FISH analysis
DNA samples from tails of mice and blood of goats were
obtained 2–3 weeks and ~4 days after birth, respectively.
Transgenic mice and goats were initially identified by PCR
and subsequently confirmed by Southern blot analysis.
PCR was performed by employing three sets of primers for
each sample. Set A (Acb852, 5' CTT CCG TGG CCA GAA
TGG ATG GGA GTG 3'/Acb883, 5' AAG AAA AGG AGT
TCC GGG GC 3') amplified a 930 bp fragment from the 3'
end of the BChE cDNA and hSA cDNA 5' end. Set B
(Acb268, 5'AGG AGC ACA GTG CTC ATC CAG ATC 3'/
Acb659, 5' GAC GCC CCA TCC TCA CTG ACT 3') ampli-
fied a 910 bp fragment of the insulator sequence. Set C for
mice (Acb572, 5' TTC CTA GGA TGT GCT CCA GGC T 3'/
Acb255, 5' GAA ACG GAA TGT TGT GGA GTG G 3') or
goat (Acb256, 5' GAG GAA CAA CAG CAA ACA GAG 3'/
Acb312, 5' ACC CTA CTG TCT TTC ATC AGC 3') ampli-
fied a 500 bp or a 360 bp portion of an endogenous
mouse or goat β-casein gene, respectively, and ensured
that the extracted DNA contained no inhibitors for the
PCR reaction and it could therefore be amplified. Upon
amplification the DNA samples were electrophoresed on
a 1% agarose gel. Confirmation of intactness and copy
number of the transgene was assessed with Southern blot
analysis [28] using the DIG system (Roche Diagnostics).
The transgene integration sites in the transgenic goats
were investigated by FISH analysis with the protocol
described elsewhere [28].
Purification of BChE/hSA produced in vitro and in vivo
All the purification procedures were performed at 4°C
unless otherwise noted. For BChE/hSA produced in vitro
~30 liters of cell media were harvested from the hollow
fiber system for purification. The media were brought to
50% saturation with solid ammonium sulfate, incubated
for 1 h and centrifuged at 12,000 × g for 30 min. Superna-
tant was collected, brought to 80% saturation with
ammonium sulfate and incubated for 1 h prior to centrif-
ugation at 12,000 × g for 30 min. The pellet was resus-
pended in buffer A (20 mM sodium phosphate, pH 7.4, 1
mM EDTA) and dialyzed overnight against buffer B
(buffer A + 100 mM NaCl). The dialysate was loaded onto
a procainamide affinity column, synthesized in house and
equilibrated in buffer B. The column was washed with 10
bed volumes of buffer C (buffer A + 150 mM NaCl), and
eluted with buffer D (buffer A + 300 mM NaCl). Fractions
were assayed for BChE activity and those with higher-
than-background BChE activity were pooled. The pool
was dialyzed overnight against buffer A and stored at 4°C.
For BChE/hSA purification from the milk of transgenic
goats, a similar methodology was developed based on
precipitation of contaminating proteins with ammonium
sulfate, followed by an additional HQ50 ion exchange
chromatography (Applied BioSystems, Foster City, CA)
prior to the procainamide affinity column chromatogra-
phy [14]. The purity of the material was assessed by SDS-
PAGE silver staining (Invitrogen) as described by the
manufacturer.
For a BChE preparation with >70% tetramer, recombinant
BChE produced from milk of transgenic goats was puri-
fied [14] and polyproline (Sigma-Aldrich) was added to
the purified recombinant BChE at molar ratio of 2:1 to
maximize tetramer formation. The mixture was incubated
at room temperature for 2 h. Excess polyproline was
removed by ultrafiltration with a 30 kDa cut-off nitrocel-
lulose membrane. The percentage of tetramer was meas-
ured using (SEC)-HPLC [14].
BChE activity assay (Ellman assay), non-denaturing BChE 
activity gel staining, Western blot analysis and SEC-HPLC
All the procedures were described in detail previously
[14]. For SEC-HPLC protein size distribution was deter-
mined and compared with reference proteins including
purified human plasma BChE (kindly provided by Dr. O.
Lockridge, University of Nebraska, Omaha, NE). By using
area counts, percentages of oligomeric forms of the fusion
protein were determined.
Pharmacokinetic study of in vitro purified BChE/hSA
Animals were used with Guidelines on the care and use of
experimental animals from CCAC. All experimental pro-
tocols were approved by the institutional animal care
committee. Purified BChE/hSA fusion protein produced
in vitro was injected i.v. into 2 juvenile pigs of ~20 kg (10
mg/kg, using a converting equation of 720 units = 1 mg
purified plasma huBChE [29]). As a control, a transgeni-
cally produced recombinant BChE preparation containing
more than 70% tetramer was also injected i.v. into 4 juve-
nile pigs at a dose of 10 mg/kg. The pigs were anesthetized
with isoflurane and 30% oxygen for placement of the
catheters and prior to anesthetic delivery a control blood
sample was drawn. Following anesthesia a second sample
was taken and the plasma used for the control BChE activ-BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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ity. Following injection of the various samples, blood was
taken at 1, 2.5, 5, 15, 30 min then at 1 h, 2 h, 4 and 8 h
from the cannulated ear vein. After 8 h the animals were
allowed to awaken and further samples were taken at 24,
48, 72 and 96 h (and in some cases beyond) from the
external jugular vein. Plasma was produced from the
drawn blood and analyzed using the Ellman assay. The
data analysis was performed by MDS Pharma Services
(Montreal, QC, Canada) using NONMEM®  version 5
(GloboMax, LLC, Ellicott City, MD) with a 2-compart-
ment model.
In vitro inhibition of BChE/hSA by OP agents
Various amounts of nerve agent solutions (2–2,000 nM)
were added to milk samples collected from a F1 transgenic
mouse. The samples containing the fusion protein were
diluted with 0.1 M Tris-HCl (pH 8.0) at × 100 fold dilu-
tions and incubated at 25°C for 5 min. Milk collected
from a negative FVB mouse and treated in a similar way
served as the negative control. Residual BChE activity (%)
was measured by the Ellman assay at 25°C. Data were
analyzed and plotted using Microsoft Excel (Microsoft,
Redmond, WA).
BChE/hSA fusion protein expression, activity and oligomeric forms Figure 1
BChE/hSA fusion protein expression, activity and oligomeric forms. (A) BChE activity gel staining of samples from BChE/hSA 
produced in vitro and in vivo. Unless otherwise noted 15 µl (10 units/ml) of samples were loaded onto each lane of a precast 4–
20% Tris-Glycine polyacrylamide non-denaturing gel in the following order: lane 1, purified plasma huBChE (tetramer indi-
cated); lane 2, Harvest 8 of conditioned media of clone 35 from the hollow fiber system; lane 3, control conditioned media; 
lane 4, diluted milk sample from a F1 transgenic mouse, 307-1A7; lane 5, diluted milk sample from a F2 transgenic mouse, 307-
1A7A4; lane 6, diluted milk sample from a nontransgenic FVB mouse (1:30); lane 7, diluted milk sample from a transgenic goat, 
2237; lane 8, diluted milk sample from a transgenic goat, 2177; lane 9, purified BChE/hSA sample from milk of the goat 2177; 
lane 10, diluted milk sample from a nontransgenic goat (1:30). (B) Western blot analysis under denaturing and reducing condi-
tions. Immunodetection was performed with a polyclonal anti-huBChE antibody (Dako, Mississauga, ON, Canada). Unless oth-
erwise noted 15 µl (10 units/ml) of samples were loaded onto each lane of a precast 4–20% Tris-Glycine polyacrylamide gel in 
the following order: lane 1, Biotinylated molecular markers (Cell Signaling Technology, Inc., Danvers, MA); lane 2, purified 
plasma huBChE; lane 3, Harvest 8 of conditioned media of clone 35 from the hollow fiber system; lane 4, control conditioned 
media; lane 5, diluted milk sample from a F1 transgenic mouse, 307-1A7; lane 6, diluted milk sample from a nontransgenic FVB 
mouse (1:30); lane 7, diluted milk sample from a transgenic goat, 2237; lane 8, diluted milk sample from a transgenic goat, 2177; 
lane 9, purified BChE/hSA sample from milk of the goat 2177; lane 10, diluted milk sample from a nontransgenic goat (1:30). (C) 
SEC-HPLC analysis of milk from a transgenic mouse, 307-1A7A2. (D) SEC-HPLC analysis of milk from the transgenic goat, 
2177.BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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Results
In vitro production and purification of BChE/hSA fusion 
protein
Production of the fusion protein from a selected clone,
clone 35, using a hollow fiber system after transfection
with the in vitro DNA expression vector, CMV/BChE/hSA,
in BHK cells was initiated to generate sufficient material
(~1 g in ~30 liters of media, 30 mg/liter) for purification
with ammonium sulfate precipitation, followed by pro-
cainamide affinity chromatography. The purified fusion
protein was analyzed by SDS-PAGE silver staining, indi-
cating that the isolated material was ~50% pure (data not
shown).
An activity gel staining using conditioned media from
BHK cells expressing the fusion protein demonstrated the
secretion of an active enzyme, with the major band
migrating faster than the plasma huBChE tetramer (Fig.
1A lane 2). Western blot analysis under denaturing and
reducing conditions confirmed the expression of the
fusion protein in BHK cells with expected molecular mass
of ~150 kDa (Fig. 1B lane 3). A band appeared at ~90 kDa
in the lane and it may belong to proteolytic products of
the fusion protein. The BChE activity from the best pro-
ducing clone was estimated at 0.7–0.75 units per million
cells per 24 h.
Pharmacokinetic study on BChE/hSA produced in vitro
Plasma BChE activity in juvenile pigs following a single
i.v. injection of 10 mg/kg BChE/hSA, produced in vitro
and partially purified, or 10 mg/kg tetramer-enriched
BChE, produced in vivo and purified, was analyzed using
the Ellman assay with background BChE activity sub-
tracted (Fig. 2A and 2B). The BChE activity curves of the
fusion protein followed multi-exponential decay. How-
ever, the curves of tetramer-enriched BChE did not follow
the multi-exponential decay; instead they appeared to
have a more rapid rate of decline from the peak until
~200% above the control activity. Pharmacokinetic
parameters derived from 2-compartmental analysis of the
i.v. groups are summarized in Table 1. The results clearly
revealed a substantial enhancement of the plasma half-life
of the fusion protein (~32 h) when compared with the
recombinant BChE transgenically produced in goat milk
and enriched to contain more than 70% tetramer (~3 h)
(Table 1; Fig. 2).
Identification of transgenic mice and expression of the 
fusion protein in the milk
Three F0 founder mice, two females and one male, were
generated by pronuclear microinjection with the in vivo
DNA expression vector, bCN/BChE/hSA. Southern blot
analysis revealed that one transgenic female mouse car-
ried ~40 copies of the transgene whereas the other two
carried 1–2 copies in their genomes, respectively (Table
2). Two transgenic founders, the female with ~40 trans-
Clearance of BChE/hSA fusion protein produced in vitro (A) and a transgenically produced BChE preparation containing >70%  tetramer (B) in juvenile pigs in vivo Figure 2
Clearance of BChE/hSA fusion protein produced in vitro (A) and a transgenically produced BChE preparation containing >70% 
tetramer (B) in juvenile pigs in vivo. Juvenile pigs were injected i.v. with the proteins and plasma BChE activity (%) above control 
(untreated pigs, ~1.6 unit/ml) was plotted versus time (hours) for each animal.BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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gene copies and a male, bred with wild type mice of the
same strain, transmitted the gene construct to their off-
spring. Upon breeding of the male line a Mendelian fash-
ion of transmission was observed with ~50% of the F1
littermates found to be transgenic. When the female line
was bred, a high level of transmission (~90%) was
observed, indicating multiple integration sites of the
transgene. Milk samples, collected from transgenic female
mice, were analyzed using the Ellman assay, BChE activity
gel staining, SEC-HPLC and Western blot. There were no
detectable levels of BChE/hSA in the F1 females from the
male line, probably due to the low copy number of the
transgene integrated (data not shown). However, the
results from the female line clearly indicated that the
BChE activity was present in the milk of the founder and
its female offspring with different transgene copies inte-
grated (Table 2). BChE activity gel staining and analysis of
the raw milk samples by SEC-HPLC revealed that the
fusion protein consisted of a predominant form (~85%)
corresponding to dimers in size and a minor monomer
form (~13%) (Fig. 1A lanes 4 & 5; Fig. 1C). The fusion
protein was confirmed to have the expected molecular
mass of ~150 kDa when analyzed by Western blot under
denaturing and reducing conditions (Fig. 1B lane 5).
Inhibition of BChE by OP nerve agents in vitro
Milk samples collected from a transgenic mouse and a
nontransgenic mouse were incubated with various ratios
of tabun (GA), sarin (GB), soman (GD) and VX in the
nerve agent binding and inhibition assay (Fig. 3). The
results indicated that the amount of the nerve agents
required to inhibit 100% of enzyme activity (Fig. 3A) was
Table 1: Summary of the average (CV%) pharmacokinetic parameters from post-hoc bayesian estimates following protein i.v. injection 
in juvenile pigs
Form of protein n K (1/h) K12 (1/h) K21 (1/h) Vc (L) Thalf (h) Vehicle (unit/mL)
BChE/hSA produced in vitro 2 0.0579 (0.0) 0.0993 (100) 0.103 (99.9) 0.581 (0.0) 32.4 (29.8) 1.83 (0.0)
BChE produced transgenically (>70% 
tetramer)
4 0.689 (28.4) 0.553 (18.4) 0.592 (0.000845) 0.120 (42.9) 2.74 (12.6) 1.45 (0.0)
CV%: The intersubject variation, reported as a percentage (%) of coefficient of variation;
K: The elimination rate constant from the central compartment;
K12: The rate constant of the protein from the central to the first peripheral compartment;
K21: The rate constant of the protein from the first peripheral to the central compartment;
Vc: The volume of the central compartment following i.v. administration;
Thalf: The apparent terminal elimination half-life;
Vehicle: The response detected by the analytical assay that is considered as background activity in untreated juvenile pig plasma, not related to the 
administration of the protein, using 720 units = 1 mg purified plasma huBChE and assay conditions as described in. [29].
Table 2: Summary of transgenic animals producing BChE/hSA fusion protein
Transgenic animal Animal ID Generation Sex Transgene copy number Integration site Expression in milk (g/liter)*
Mouse 307-1 F0 F ~40 ND 0.27
307-1A2 F1 F 1–2 ND 0.40
307-1A7 F1 F 8–10 ND 0.41
307-1A7A2 F2 F 8–10 ND 0.24
307-1A7A4 F2 F 1–2 ND 0.41
Goat 2176 F0 F 18–28 2 0.06
2177 F0 F 6–10 1–2 1.10
2178 F0 F 18–28 2–3 0.07
2229 F0 F 10–14 1–2 0.07
2231 F0 F 10–14 1–2 0.04
2232 F0 F 10–14 1–2 0.09
2233 F0 F 10–14 1–2 0.08
2234 F0 F 10–14 1–2 0.35
2236 F0 F 10–14 1–2 0.10
2237 F0 F 10–14 1–2 0.23
2238 F0 F 10–14 1–2 0.09
2239 F0 F 10–14 1–2 0.11
*The concentrations for expression of BChE/hSA, estimated by densitometry where 720 units = 1 mg of purified plasma huBChE. [29], were the 
average of two independent assays. ND = not determined.BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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in good agreement with that of plasma huBChE [4], as
well as recombinant huBChE expressed in the milk of
transgenic mice [14], suggesting that the fusion protein is
similar to the plasma huBChE with comparable broad
spectrum properties against a variety of nerve agents.
Since the endogenous mouse BChE activity in the milk of
non-transgenic mice is minimal [14], it is reasonable that
no change of residual BChE activity in the non-transgenic
milk was detected despite the addition of nerve agents
with increased concentrations (Fig. 3B).
Identification of transgenic goats and purification of the 
fusion protein in the milk
A total of 19 female transgenic goats were generated using
nuclear transfer in 3 primary goat fetal fibroblast cell lines
transfected with the in vivo DNA expression vector, Neo-
bCN/BChE/hSA, as determined by PCR, Southern blot
and FISH analysis. 1–3 integration sites and a variety of
transgene copies in their respective genomes were
detected. While some of the clones manifested behavioral
abnormalities and/or susceptibility to respiratory disease,
most of these conditions improved dramatically or totally
disappeared after one year of age [30]. Of 19 cloned trans-
genic goats 12 have been induced hormonally into lacta-
tion [31]. Goat 2177 expressed BChE/hSA in the milk in
average ~1.1 g/liter whereas the others expressed at 0.04–
0.3 g/liter, as determined by the Ellman assay (Table 2).
Further, goat 2177 has entered into natural lactation, pro-
ducing 1.1 g/liter of the fusion protein. ~7.5 g of bioactive
BChE/hSA has been purified from ~8.7 liters of milk by a
HQ 50 ion exchange chromatography, followed by a pro-
cainamide affinity chromatography (Fig. 4). The purity as
assessed by SDS-PAGE silver staining is estimated to be
>90% (Fig. 4 lane 8). Specific activity of the purified
enzyme is ~400 units/mg. Non-denaturing polyacryla-
mide gels stained for BChE activity and SEC-HPLC analy-
sis of the raw milk samples indicated that the fusion
protein consisted of a major form (~60%) corresponding
in size to dimers, a minor monomeric form (~28%) and
some other minor components which may represent pro-
teolytic products (Fig. 1A lanes 7–9; Fig 1D). Western blot
under denaturing and reducing conditions revealed a pro-
tein with the expected molecular mass of ~150 kDa (Fig.
1B lanes 7–9). A minor band appeared at ~90 kDa in the
lanes, suggesting proteolytic products of the fusion pro-
tein.
Discussion
We have demonstrated that kilogram quantities of recom-
binant huBChE can be purified from the milk of trans-
genic goats where it is produced at concentrations of 1–5
g/liter and the recombinant BChE produced in the milk of
transgenic goats was shown to be likely a useful bioscav-
enger of OP nerve agents [14,15]. The main objective of
this study was to examine if the fusion of huBChE and
hSA would act in a manner to yield a novel protein that
retains the recombinant BChE's binding and inhibition
against OP nerve agents and the slow clearance of hSA.
During the course of the study different forms of recom-
binant BChE/hSA were produced. To prove the concept
In vitro binding and inhibition of BChE/hSA fusion protein contained in the milk of transgenic mice by OP nerve agents Figure 3
In vitro binding and inhibition of BChE/hSA fusion protein contained in the milk of transgenic mice by OP nerve agents. Binding 
and inhibition were performed with diluted raw mouse milk materials from a F1 transgenic mouse, 307-1A7 (A) and a control 
FVB mouse (B, 0.086 ± 0.03 unit/ml). The reactions were carried out in the presence of tabun (GA, ), sarin (GB, ■ ), soman 
(GD, ▲ ) and VX (● ), respectively. Residual BChE activity was measured by the Ellman assay. Data points represent the mean 
± SD from duplicates in each mouse.BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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and due to availability of materials, partially purified
BChE/hSA from BHK cells was used first in the pharma-
cokinetic study with the purified recombinant human
BChE as a control. While the purity of the fusion protein
may be a concern it is difficult to envision how impurities
would affect the pharmacokinetics of the protein since
only the active (and hence actual) material was measured.
Then transgenic mice were generated. Non-purified milk
samples were obtained from a transgenic mouse and used
for the nerve agent in vitro binding and inhibition assay,
as it is not practical to purify recombinant proteins from
milk of transgenic mice because of small volume. When
the nerve agent binding and inhibition experiment was
performed the only available material was from trans-
genic mice. There was a few years' delay from producing
the fusion protein from BHK cells to obtaining the protein
from transgenic goats. Nevertheless, both the pharmacok-
inetic study and the in vitro nerve agent binding and inhi-
bition assay, although using different forms of the fusion
protein, suggested that a novel polypeptide retaining both
properties of huBChE and hSA is produced in vitro and in
vivo. The production of the fusion protein in the milk of
transgenic goats provided further evidence that it is possi-
ble to produce such a protein in large scale and in a cost-
effective way.
Given the fact that the recombinant human BChE
expressed in the milk of transgenic goats is mainly in the
dimer form [14], it is not surprised that the major eluted
fusion protein peaks from the milk of transgenic mice and
goats by SEC-HPLC are dimers in size. Dimers also
appeared in other hSA-fused proteins although they were
only present as minor components [32].
(Gly)6-Ser linker was engineered to fuse the hSA with the
huBChE, facilitating the probability of independent fold-
ing as well as independence of action of the two portions
of the fusion protein. Although its beneficial effects
remain to be explored further, similar strategies have been
successfully used in generation of other functional fusion
proteins, for example, heavy and light chain Ig fusion pro-
teins [33] and a recombinant hirudin genetically fused to
albumin [34].
Other efforts to improve pharmacokinetic profiles of ther-
apeutic proteins have included addition of dextran parti-
cles and polyethylene glycol (PEG) chains to the proteins.
PEGylation often improves the pharmacokinetic and tox-
icity profiles of a recombinant protein and it may also
reduce its immunogenicity [35]. However, high cost of
PEGylation reagents and significantly reduced specific
activity relative to some unmodified proteins [36,37] are
among negative factors to be considered when PEGylation
is assessed. The data presented in this study as well as from
other hSA-fused therapeutic proteins suggest that the dis-
advantages of the PEGylation can be practically overcome
by fusing a therapeutic protein to hSA genetically. Clinical
trials of several fusion proteins, for example, hSA fused to
human growth hormone, interleukin-2 and interferon
alpha, all demonstrated safety, prolonged half-life, and
biological activity [17-19].
It is well known that the mammary gland of transgenic
animals is a good system for recombinant protein produc-
tion [38]. A variety of recombinant human proteins,
including immunoglobin, growth hormone and clotting
factors, have been expressed and secreted in the milk of
transgenic animals [39]. Expression of BChE/hSA in the
milk of transgenic mice and goats represents just another
good example. Since the expression level of BChE/hSA
was assessed based on the BChE activity the actual secre-
tion of the total BChE/hSA protein in the milk of trans-
genic animals should be at least doubled as half of the
fusion protein is composed of the hSA. Based on a math-
ematically calculated model it has been suggested that the
upper limit doses of 134, 115, and 249 mg/70 kg of
human plasma derived BChE are sufficient to protect RBC
SDS-PAGE silver staining for purification of BChE/hSA fusion  protein from the milk of the transgenic goat, 2177 Figure 4
SDS-PAGE silver staining for purification of BChE/hSA fusion 
protein from the milk of the transgenic goat, 2177. 1 µg of 
samples were loaded onto each lane of a precast 4–20% Tris-
Glycine polyacrylamide gel under denaturing and reducing 
conditions in the following order: lane 1, molecular weight 
marker (Bio-Rad, Mississauga, ON, Canada); lane 2, HQ 50 
column load; lane 3, HQ50 column flow-through; lane 4, 
HQ50 column elution; lane 5, HQ50 column cleaning; lane 6, 
procainamide column flow-through; lane 7, molecular weight 
marker (Bio-Rad); lane 8, procainamide column elution.BMC Biotechnology 2008, 8:50 http://www.biomedcentral.com/1472-6750/8/50
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AChE above 30% of baseline activity following a chal-
lenge with 1 × LD50 VX, soman, and sarin, respectively,
thus preventing manifestation of severe toxic signs in
human [40]. The predictions of huBChE doses were vali-
dated by in vitro experiments and data of published
human studies. Therefore it is reasonable to predict that
the upper limit doses described above for the plasma-
derived huBChE may be doubled for the fusion protein to
achieve the same protection. The experimental results pre-
sented in this study, along with other lines of evidence
[14,38], indicate that transgenic production could pro-
vide high level expression of recombinant proteins in the
milk of transgenic animals with flexible scale-up and sig-
nificantly lower costs and risks compared to cell culture
based production systems. This technique enables the
large-scale production of complex or unique molecules
that may not be produced efficiently by any other systems.
The present study thus provides evidence to support the
conclusion that in addition to the production of recom-
binant huBChE in the milk of transgenic goats [14], suffi-
cient quantities of BChE/hSA can be produced from
transgenic goats to serve as an effective and reliable source
of BChE for prophylaxis and post-exposure treatment,
alternatively to the purification of plasma huBChE.
Conclusion
The pharmacokinetic study and the in vitro nerve agent
binding and inhibition assay suggested that a huBChE/
hSA fusion protein retaining both properties of huBChE
and hSA is produced in vitro in BHK cells and in vivo in the
milk of transgenic animals. It is possible to produce such
a fusion protein in large scale and in a cost-effective way
in the milk of transgenic goats.
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